KEROS THERAPEUTICS INC
NASDAQ: KROS (Keros Therapeutics, Inc.)
Last update: 1 hour ago11.73
0.25 (2.18%)
| Previous Close | 11.48 |
| Volume | 189,816 |
| Price / Earnings (Forward) | 48.78 |
| Price / Sales | 20.19 |
| Price / Book | 0.840 |
| 52 Weeks Range |
| Profit Margin | 1.96% |
| Operating Margin (TTM) | 71.97% |
| Diluted EPS (TTM) | -0.170 |
| Quarterly Revenue Growth (YOY) | 254,413.31% |
| Total Debt/Equity (MRQ) | 2.53% |
| Current Ratio (MRQ) | 19.29 |
| Operating Cash Flow (TTM) | 44.86 M |
| Levered Free Cash Flow (TTM) | 30.29 M |
| Return on Assets (TTM) | -1.01% |
| Return on Equity (TTM) | 0.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Keros Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.83 |
|
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.31% |
| % Held by Institutions | 109.35% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nantahala Capital Management, Llc | 30 Jun 2026 | 1,410,419 |
| Orbimed Advisors Llc | 30 Jun 2026 | 759,155 |
| Federated Hermes, Inc. | 30 Jun 2026 | 700,427 |
| Madison Avenue Partners, Lp | 30 Jun 2026 | 626,583 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 605,445 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |